Effect of Sitagliptin on Glycemic Excursion and Cognitive Function among Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment

doi:10.12114/j.issn.1007-9572.2018.31.012

Abstract

Abstract: Objective　To explore the clinical effect of sitagliptin on glycemic excursion and cognitive function among elderly patients with type 2 diabetes mellitus （T2DM） and mild cognitive impairment.Methods　Seventy-eight elderly T2DM patients with mild cognitive impairment were equally randomized into treatment group and control group，receiving 24-week treatment with metformin combined with sitagliptin，metformin combined with gliclazide，respectively.BMI，fasting blood glucose（FG），2-hour postprandial blood glucose（2 hPG），and glycosylated hemoglobin（HbA1c） were measured at baseline and at the end of the 24th week of treatment.Blood glucose level was monitored over a 3-day period with continuous glucose monitoring system （CGMS） before and after treatment，and according to the monitored results，the mean amplitude of glycemic excursions（MAGE），mean of daily differences（MODD），standard deviations of blood glucose（SDBG），mean postprandial glycemic excursion（MPPGE） were calculated.Cognitive function was evaluated with Montreal Cognitive Assessment （MoCA） before and after treatment.Parameters of blood glucose，glycemic excursions and cognitive functions before and after treatment were compared.Results　The mean BMI，FBG，2 hPG，and HbA1c，MAGE，MODD，SDBG，MPPGE，and mean MoCA core were similar in both groups at baseline（P>0.05）．After 6 months of treatment，although mean BMI，FBG，2 hPG and HbA1c were still similar in both groups（P>0.05），MAGE，MODD，SDBG，and MPPGE were much lower and mean MoCA score was much higher in the treatment group compared with the control group（P<0.05）．Conclusion　Sitagliptin may improve the cognitive function by reducing glycemic excursions in elderly T2DM patients with mild cognitive impairment.

Key words: Diabetes mellitus, type 2；Mild cognitive impairment；Sitagliptin；Glycemic excursion

摘要： 目的　研究西格列汀对老年2型糖尿病（T2DM）轻度认知障碍（MCI）患者血糖漂移及认知功能的影响。方法　选择老年T2DM轻度认知障碍患者78例，随机分为研究组39例（西格列汀+二甲双胍组）和对照组39例（格列齐特+二甲双胍组）。两组患者联合用药前及用药24周后测量体质指数（BMI）、空腹血糖（FBG）、餐后2 h血糖（2 hPG）、糖化血红蛋白（HbA1c）。所有患者治疗前后均接受72 h动态血糖监测（CGMS），根据监测结果计算日内平均血糖漂移幅度（MAGE）、日间血糖漂移幅度（MODD）、血糖水平标准差（SDBG）、平均餐后血糖漂移幅度（MPPGE），治疗前后用蒙特利尔认知评估量表（MoCA）评估认知功能。观察治疗前及药物治疗6个月后血糖、血糖漂移、认知功能的变化。结果　治疗前，两组BMI、FBG、2 hPG、HbA1c、MAGE、MODD、SDBG、MPPGE、MoCA评分差异无统计学意义（P>0.05）。治疗后，研究组MAGE、MODD、SDBG、MPPGE低于对照组，MoCA评分高于对照组，差异有统计学意义（P<0.05）；两组BMI、FBG、2 hPG、HbA1c差异无统计学意义（P>0.05）。结论　西格列汀可能通过降低老年T2DM轻度认知障碍患者的血糖漂移进而改善其认知功能。

关键词: 糖尿病, 2型, 轻度认知障碍, 西格列汀, 血糖漂移

XIA Wei,ZHANG Ling,HU Ziying. Effect of Sitagliptin on Glycemic Excursion and Cognitive Function among Elderly Type 2 Diabetic Patients with Mild Cognitive Impairment[J]. Chinese General Practice, 2018, 21(31): 3837-3840. DOI: 10.12114/j.issn.1007-9572.2018.31.012.
夏威,张菱,虎子颖. 西格列汀对老年2型糖尿病轻度认知障碍患者血糖漂移和认知功能的影响研究[J]. 中国全科医学, 2018, 21(31): 3837-3840. DOI: 10.12114/j.issn.1007-9572.2018.31.012.

References

［1］ALAGIAKRISHNAN K，ZHAO N，MEREU L，et al．Montreal Cognitive Assessment is superior to Standardized Mini-Mental Status Exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus［J］．Biomed Res Int，2013，2013：186106．DOI：10.1155/2013/186106.
［2］ZHOU Y，ZHAO Y，XIE H，et al．Alteration in amyloid β42，phosphorylated tau protein，interleukin 6，and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats：correlation of amyloid β42 with changes in glucose metabolism［J］．Behav Brain Funct，2015，11：24．DOI：10.1186/s12993-015-0069-5.
［3］SAKURAI I．Preventive strategy for cognitive decline in elderly with diabetes mellitus［J］．Nihon Rinsho，2014，72（4）：692-696．
［4］贺钰梅，韩秀平，汪丽丽，等．长期强化降糖治疗对2型糖尿病患者生活质量及心血管事件的影响研究［J］．实用心脑肺血管病杂志，2016，24（4）：31-34．DOI：10.3969/j.issn.1008-5971.2016.04.009.
HE Y M，HAN X P，WANG L L，et al．Impact of long-term intensive hypoglycemic therapy on quality of life and cardiovascular events of patients with type 2 diabetes mellitus［J］．Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease，2016，24（4）：31-34．DOI：10.3969/j.issn.1008-5971.2016.04.009.
［5］RIZZO M R，BARBIERI M，BOCCARDI V，et al．Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment［J］．J Gerontol A Biol Sci Med Sci，2014，69（9）：1122-1131．DOI：10.1093/gerona/glu032.
［6］OGEDENGBE S，EZEANI I U，AIHANUWA E．Comparison of clinical and biochemical variables in type 2 diabetes mellitus patients and their first-degree relatives with metabolic syndrome in Benin City，Nigeria：a cross sectional case controlled study［J］．Endocr Regul，2016，50（1）：32-40．DOI：10.1515/enr-2016-0007.
［7］CIESIELSKA N，SOKOLOWSKI R，MAZUR E，et al．Is the Montreal Cognitive Assessment （MoCA） test better suited than the Mini-Mental State Examination （MMSE） in mild cognitive impairment（MCI） detection among people aged over 60? Meta-analysis［J］．Psychiatr Pol，2016，50（5）：1039-1052．DOI：10.12740/PP/45368.
［8］KOVATCHEV B P．Metrics for glycaemic control - from HbA1c to continuous glucose monitoring［J］．Nat Rev Endocrinol，2017，13（7）：425-436．DOI：10.1038/nrendo.2017.3.
［9］刘福平，张星光，陈彬．二甲双胍联合西格列汀或格列美脲对2型糖尿病血糖波动和氧化应激的影响［J］．中国现代医学杂志，2015，25（33）：71-74．DOI：10.3969/j.issn.1005-8982.2015.33.014.
LIU F P，ZHANG X G，CHEN B．Effect of Metformin combined with Sitagliptin or Glimepiride on blood glucose variability
and oxidative stress markers in patients with type 2 diabetes
mellitus［J］．China Journal of Modern Medicine，2015，25（33）：71-74．DOI：10.3969/j.issn.1005-8982.2015.33.014.
［10］RIZZO M R，MARFELLA R，BARBIERI M，et al．Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients［J］．Diabetes Care，2010，33（10）：2169-2174．DOI：10.2337/dc10-0389.
［11］何焰鹏，刘国荣，王宝军，等．血糖波动与认知功能障碍关系研究进展［J］．中国当代医药，2013，20（20）：28-30．DOI：10.3969/j.issn.1674-4721.2013.20.010.
HE Y P，LIU G R，WANG B J，et al．Research progress of relationship between blood sugar fluctuation and cognitive dysfunction［J］．China Modern Medicine，2013，20（20）：28-30．DOI：10.3969/j.issn.1674-4721.2013.20.010.
［12］HARTLEY P，SHENTU Y，BETZ-SCHIFF P，et al．Efficacy and tolerability of Sitagliptin compared with Glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control：a randomized，double-blind，non-inferiority trial［J］．Drugs Aging，2015，32（6）：469-476．DOI：10.1007/s40266-015-0271-z.
［13］向勤，吴逊.初诊2型糖尿病应用西格列汀与二甲双胍治疗对血糖波动及微炎症状态的影响［J］．海南医学院学报，2016，22（15）：1653-1655，1659．DOI：10.13210/j.cnki.jhmu.20160415.010.
XIANG Q，WU X.Influence of sitgliptin and metformin treatment on glucose fluctuation and serum inflammatory factors in prel iminary diagnosed type 2 diabetes mellitus［J］．Journal of Hainan Medical University，2016，22（15）：1653-1655，1659．DOI：10.13210/j.cnki.jhmu.20160415.010.
［14］ISIK A T，SOYSAL P，YAY A，et al．The effects of sitagliptin，a DPP-4 inhibitor，on cognitive functions in elderly diabetic patients with or without Alzheimer's disease［J］．Diabetes Res Clin Pract，2017，123：192-198．DOI：10.1016/j.diabres.2016.12.010.
［15］PINTANA H，APAIJAI N，CHATTIPAKORN N，et al．DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats［J］．J Endocrinol，2013，218（1）：1-11．DOI：10.1530/JOE-12-0521.
［16］万亨，沈洁，赵德福，等．西格列汀联合胰岛素泵治疗新诊断2型糖尿病血糖波动研究［J］．中国实用内科杂志，2014，34（4）：375-378.
WAN H，SHEN J，ZHAO D F，et al．Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in patients with newly diagnosed type 2 diabetes mellitus receiving insulin-pump therapy［J］．Chinese Journal of Practical Internal Medicine，2014，34（4）：375-378.
［17］GAULT V A，LENNOX R，FLATT P R.Sitagliptin，a dipeptidyl peptidase-4 inhibitor，improves recognition memory，oxidative stress and hippocampal neurogenesis andupregulates key genes involved in cognitive decline［J］．Diabetes Obes Metab，2015，17（4）：403-413．DOI：10.1111/dom.12432.
［18］CHALICHEM N S S，GONUGUNTA C，KRISHNAMURTHY P T，et al．DPP-4 inhibitors can be a drug of choice for type 3 diabetes：a mini review［J］．Am J Alzheimers Dis Other Demen，2017，32（7）：444-451．DOI：10.1177/1533317517722005.

[1]	LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301.
[2]	LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307.
[3]	YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295.
[4]	ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019.
[5]	CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724.
[6]	ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649.
[7]	ZHAO Xiaohua, DU Lin, GAO Shengnan, JIANG Ziyun. Multiple Deep Muscle Abscesses in Type 2 Diabetes in the Elderly: Report of One Case and Literature Review [J]. Chinese General Practice, 2023, 26(29): 3715-3718.
[8]	LUO Dan, XU Jingjing, WANG Yubing, LI Mingzi, FORBES Angus. Development and Preliminary Practice of Resilience-oriented Structured Treatment and Educational Program for Adolescents with Type 1 Diabetes [J]. Chinese General Practice, 2023, 26(27): 3423-3429.
[9]	DONG Yanan, JIANG Xiaorui, WANG Kai, ZONG Chuanchong, LIN Guodong, LI Xiangqing, LIN Chunxiao, CHI Juntao. The Effect of Modified Tibial Transverse Transport Technique in the Treatment of Wagner Grade Ⅲ and Ⅳ Diabetic Foot Patients [J]. Chinese General Practice, 2023, 26(27): 3411-3416.
[10]	LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268.
[11]	GU Yunjie, SONG Jing, YIN Jun. Clinical Study on Low-carbon Diet for Endogenous-insulin-deficient Diabetes Patients [J]. Chinese General Practice, 2023, 26(26): 3308-3313.
[12]	KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258.
[13]	CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245.
[14]	FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251.
[15]	HE Rong, ZHANG Li, LI Peng, ZHANG Xiaoling, ZHANG Guo, ZANG Yiran, WU Shouling, SUN Lixia. Immediate Effects of Aerobic Exercise on Arterial Stiffness in a Male Population with Different Blood Glucose Levels [J]. Chinese General Practice, 2023, 26(24): 2997-3004.